Drug Insights

Is Avapritinib approved by the FDA?

27 June 2024
3 min read

Yes, Avapritinib, marketed under the brand name Ayvakit, is FDA approved. The U.S. Food and Drug Administration (FDA) approved Avapritinib on January 9, 2020, for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST) harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations.

What is Avapritinib?

Avapritinib is a medication used to treat certain types of cancers and rare blood disorders. It belongs to the class of drugs known as multikinase inhibitors. The drug is administered orally in tablet form and is available in various dosages, including 25 mg, 50 mg, 100 mg, 200 mg, and 300 mg.

Uses of Avapritinib

  1. Gastrointestinal Stromal Tumors (GIST):
    • Indication: Avapritinib is used to treat adults with unresectable or metastatic GIST with a PDGFRA exon 18 mutation.
    • Dosage: The usual dose for GIST is 300 mg orally once a day until disease progression or unacceptable toxicity occurs.
  2. Systemic Mastocytosis:
    • Advanced Systemic Mastocytosis (AdvSM): Includes aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm, and mast cell leukemia.
      • Dosage: 200 mg orally once a day.
    • Indolent Systemic Mastocytosis (ISM):
      • Dosage: 25 mg orally once a day.

Important Precautions

  • Genetic Marker: Patients must have a specific genetic marker (an abnormal PDGFRA gene) for the medication to be effective in treating GIST.
  • Blood Counts: Not recommended for AdvSM or ISM patients with platelet counts below 50 x 10^9/L.
  • Pregnancy and Birth Control: Both men and women using Avapritinib should use effective birth control, as the drug can cause harm to an unborn baby or result in birth defects.

Side Effects

Avapritinib can cause several side effects, some of which can be serious. Common side effects include:

  • Nausea, vomiting, and loss of appetite
  • Stomach pain, diarrhea, or constipation
  • Fluid retention and swelling
  • Dizziness, weakness, and fatigue
  • Muscle weakness, watery eyes, rash, and hair color changes

Serious side effects that require immediate medical attention include severe headaches, vision problems, changes in mood or behavior, speech difficulties, confusion, hallucinations, severe drowsiness, trouble sleeping, and significant weakness on one side of the body.

Storage and Administration

Avapritinib should be taken on an empty stomach, at least 1 hour before or 2 hours after a meal. It should be stored at room temperature, away from moisture and heat.

Conclusion

Avapritinib (Ayvakit) is an FDA-approved medication effective in treating certain types of cancer and systemic mastocytosis. Approved on January 9, 2020, it offers targeted treatment for patients with specific genetic markers, providing a valuable option for managing these challenging conditions. Patients should consult their healthcare provider to determine if Avapritinib is suitable for their treatment regimen.

How to obtain the latest development progress of all drugs?

In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Takeda Gains European Commission Approval for FRUZAQLA in Treated Metastatic Colorectal Cancer
Latest Hotspot
3 min read
Takeda Gains European Commission Approval for FRUZAQLA in Treated Metastatic Colorectal Cancer
27 June 2024
Takeda has revealed that the European Commission has given its approval for FRUZAQLA (fruquintinib) to be used as a monotherapy for adult patients suffering from metastatic colorectal cancer.
Read →
Is Ubrogepant approved by the FDA?
Drug Insights
3 min read
Is Ubrogepant approved by the FDA?
27 June 2024
The U.S. Food and Drug Administration (FDA) approved Ubrogepant on December 23, 2019.
Read →
FDA Grants Accelerated Approval for KRAZATI® and Cetuximab Combo in Advanced KRAS G12C Mutated CRC
Latest Hotspot
3 min read
FDA Grants Accelerated Approval for KRAZATI® and Cetuximab Combo in Advanced KRAS G12C Mutated CRC
27 June 2024
Bristol Myers Squibb reveals that the U.S. FDA has granted accelerated approval for KRAZATI® (adagrasib) combined with Cetuximab for adults with previously treated, advanced, or metastatic colorectal cancer (CRC) with the KRAS G12C mutation.
Read →
Is Enhertu approved by the FDA?
Drug Insights
3 min read
Is Enhertu approved by the FDA?
27 June 2024
The U.S. Food and Drug Administration (FDA) first approved Enhertu on December 20, 2019, for the treatment of HER2-positive breast cancer.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.